AR and cancer: As a whole, the clinical literature and our theoretical results suggest the following hypothesis: that low intraprostatic AR:ligand concentrations, caused either by low serum testosterone or 5-α reductase inhibition, drive evolution towards decreased dependence upon androgens in prostate epithelium, therefore increasing the risk of cancer that is resistant to hormonal therapy.